S-1 · primary offering
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
PALI$1.22+8.48%
Palisade Bio, Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$215.88M
Float & O/S:
Inst Own:
DilutionScan read 49 of PALISADE BIO, INC.'s SEC filings and found 12 warrant series, 1 convertible, 6 shelf registrations, 3 S-1 registrations and 3 completed offerings on file for PALI. The latest dilution event on file is a registration statement on May 21, 2026. Analysis updated Oct 31, 2026.
Signal8 Summary
PALI
Pre-revenue biotech with massive dilution
Snapshot
Palisade Bio is a pre-revenue clinical-stage biotech developing treatments for gastrointestinal conditions. The company has no sales and reported a net loss of $16.8M in FY 2025, but its balance sheet is unusually strong for this stage.
What's Happening Right Now
- : Palisade Bio added biopharmaceutical veterans Robert Baltera and Jordan Zwick to its Board of Directors.
- : The company filed a shelf registration statement allowing it to offer up to $300 million of securities in the future.
- : Palisade Bio reported Q1 2026 financial results with a net loss of $0.05 per share and noted it is on track to start a Phase 2 ulcerative colitis trial in Q3 2026.
- : The company reported positive Phase 1b data for PALI-2108 in fibrostenotic Crohn's disease, showing endoscopic improvement and no serious adverse events.
Raise routes on file: effective shelf + pending S-1 · latest dilution event 166 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
May 21, 2026 · Registration
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Completed
S-1 · primary offering
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
S-1 · primary offering
Issued 2024
Proposed maximum
Shares registered
- Filed
- Effective
October 2025 Offering Pre-Funded Common Stock Warrants
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
July 2025 Warrant Inducement Replacement Common Stock Warrants
Issued 2025
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
February 2024 Warrant Inducement Replacement Common Stock Warrants
Issued 2024
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Series 2 Common Stock Warrants
Issued 2022
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Issued 2022
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Bridge and January 2022 Common Stock Warrants
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Series A Convertible Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2025
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2022
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2022
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Public offering
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your PALI trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
